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Introduction: Some previous studies have suggested a high prevalence of pulmonary embolism
(PE) during exacerbations of chronic obstructive pulmonary disease (ECOPD). The SLICE trial
aims to assess the efficacy and safety of an active strategy for the diagnosis and treatment of PE
(vs usual care) in patients hospitalized because of ECOPD.
Methods: SLICE is a phase III, prospective, international, multicenter, randomized, open-label,
and parallel-group trial. A total of 746 patients hospitalized because of ECOPD will be random-
ized in a 1:1 fashion to receive either an active strategy for the diagnosis and anticoagulant
treatment of PE or usual care (ie, standard care without any diagnostic test for diagnosing PE).
The primary outcome is a composite of all-cause death, non-fatal (recurrent) venous thrombo-
embolism (VTE), or readmission for ECOPD within 90 days after enrollment. Secondary out-
comes are (a) death from any cause within 90 days after enrollment, (b) non-fatal (recurrent)
Received: 22 November 2018 Revised: 28 January 2019 Accepted: 30 January 2019
DOI: 10.1002/clc.23161
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2019 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.
346 wileyonlinelibrary.com/journal/clc Clinical Cardiology. 2019;42:346–351.
VTE within 90 days after enrollment, (c) readmission within 90 days after enrollment, and
(d) length of hospital stay.
Results: Enrollment started in September 2014 and is expected to proceed until 2020. Median
age of the first 443 patients was 71 years (interquartile range, 64-78), and 26% were female.
Conclusions: This multicenter trial will determine the value of detecting PEs in patients with
ECOPD. This has implications for COPD patient morbidity and mortality.
Trial registration number: NCT02238639.
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1 | BACKGROUND
Chronic obstructive pulmonary disease (COPD) is a leading cause of
morbidity and mortality worldwide.1–3 COPD patients may suffer epi-
sodes of exacerbation of symptoms (ECOPD) that contribute to poor
health status, and increased healthcare costs.4 The majority of ECOPD
cases develop in response to infections5,6 and air pollution,7 but the
exact cause is not clear in up to 30% of cases.8 In addition, other fre-
quent clinical conditions may mimic the symptoms of ECOPD, includ-
ing congestive heart failure, pneumonia, pneumothorax, pleural
effusion, and pulmonary embolism (PE).8
Previous studies suggest a high prevalence of PE in ECOPD.9–12
Tillie-Leblond et al evaluated PE in a series of 197 consecutive
patients with ECOPD and found that the frequency of PE was 25%.13
However, that study was performed in a highly selected subgroup of
patients. In fact, a recent meta-analysis found a lower prevalence of
PE of 16% in ECOPD compared with previous studies.14
In patients with clinical suspicion of PE, there are some data sug-
gesting that some PE diagnoses are less severe and these patients
might not benefit from anticoagulation therapy.15 Particularly for
patients with ECOPD, some PE might be clinically unimportant, and
the risk of submitting a patient with a clinically insignificant PE to anti-
coagulant treatment might outweigh the benefit.16 Therefore, we
designed the significance of puLmonary embolism in COPD exacerba-
tions (SLICE) trial to assess the efficacy and safety of an active strat-
egy for the diagnosis and treatment of PE compared to usual care (ie,
standard care without any diagnostic test for diagnosing PE) in
patients hospitalized because of ECOPD.
2 | METHODS
SLICE complies with the standard protocol items: recommendations
for interventional trials statement.17
2.1 | Study hypothesis
This trial is designed to demonstrate the superiority of an active strat-
egy for the diagnosis and treatment of PE compared to usual care in
patients hospitalized because of ECOPD.
2.2 | Trial design and patient population
SLICE is an investigator-initiated, phase III, prospective, international,
multicenter, randomized (1:1), open-label with blind end-point evalua-
tion (PROBE), parallel-group trial (ClinicalTrials.gov identifier
NCT02238639). Consecutive adult patients with ECOPD who require
hospital admission are eligible for the study. The inclusion and exclu-
sion criteria of the SLICE trial are listed in Table 1; the flow diagram is
displayed in Figure 1. The study information for all ineligible and eligi-
ble non-recruited participants will be retained in an anonymized form
to provide detailed data on these patients in comparison to the study
participant population. The study is being conducted in 16 centers in
Spain and France.
2.3 | Randomization and trial interventions
In a patient with ECOPD who requires hospital admission, randomiza-
tion should occur in the first 24 hours after admission. The trial uses a
TABLE 1 Eligibility criteria
Inclusion criteria
Previous diagnosis of COPD: post-bronchodilator forced expiratory
volume in 1 second (FEV1)/forced vital capacity (FVC) < 0.7
Hospital admission because COPD exacerbation without initial
clinical suspicion of PE in the Emergency Department (according to
the Emergency Department physician evaluation)
Exclusion criteria
Unable to provide informed consent
Contraindication to a contrast-enhanced, PE-protocol, multidetector
computerized tomography (CTPA): allergy to intravenous contrast
medium, or renal failure defined as a creatinine clearance
<30 mL/min, based on the Cockroft-Gault equation
Anticoagulant therapy at the time of hospital admission
Pregnancy, or breast feeding
Life expectancy of less than 3 months
Diagnosis of pneumothorax, or pneumonia (fever
[temperature ≥ 38C], and purulent sputum, and new infiltrate in
chest X-ray)
Diagnosis of lower respiratory tract infection (fever
[temperature ≥ 38C], increased sputum volume and/or increased
sputum purulence)
Indication of invasive mechanical ventilation at the time of hospital
admission
Inability to comply with study assessments
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computer-generated randomization scheme. Randomization is strati-
fied by center and, within the centers, performed in blocks of 4 and
6 to ensure balanced distribution of the management groups. Ran-
domization is performed centrally through the Internet (www.
estudioslice.org), and management allocation is concealed from all
investigators.
2.3.1 | Intervention group
Patients in the intervention group have blood samples collected from
an antecubital vein, and undergo D-dimer testing within 12 hours
after randomization. Cutoff levels for defining elevated D-dimer are
defined by the Department of Clinical Chemistry at each participating
site. For patients with a negative D-dimer, a diagnosis of PE is ruled
out. For patients with a positive D-dimer, a contrast-enhanced,
PE-protocol, multidetector computerized tomography (CTPA) is
performed. CTPA results are categorized as positive for PE if an intra-
luminal filling defect is seen in (sub)segmental or more proximal
branches, and are considered negative if no filling defect is observed.
Scans are considered technically inadequate only if main or lobar pul-
monary vessels are not visualized. Although not mandatory, the proto-
col suggests the use of complete lower limb compression
ultrasonography (CCUS) to detect concomitant deep vein thrombosis
(DVT) for patients with isolated subsegmental PE.
If the diagnosis of PE is confirmed, patients receive anticoagulant
treatment according to guideline recommendations: parenteral antic-
oagulation (ie, unfractionated heparin, low-molecular-weight heparin,
or fondaparinux) overlapped and followed by vitamin K antagonists;
or parenteral anticoagulation followed by dabigatran or edoxaban; or
monotherapy with apixaban or rivaroxaban.18
2.3.2 | Control group
Patients in the control group undergo standard (ie, according to clini-
cal practice guidelines) clinical management,1,8 as deemed appropriate
by the attending physician.
2.4 | Study outcomes
The primary efficacy outcome is the composite of death from any
cause, non-fatal (recurrent) symptomatic venous thromboembolism
(VTE), or readmission for ECOPD within 90 days after enrollment.
Confirmation of (recurrent) symptomatic PE requires symptoms of PE
and a new or an extension of a previous intraluminal-filling defect in
(sub)segmental or more proximal branches on PE-protocol chest
CTPA. Confirmation of (recurrent) symptomatic DVT requires symp-
toms of DVT and the following criteria: (a) In the absence of previous
DVT investigations at baseline, a non-compressible venous segment
on ultrasonography, (b) if there were previous DVT investigations at
baseline, abnormal lower limb CCUS where compression had been
normal; or, if previously non-compressible, a substantial increase
(≥4 mm) in diameter of the thrombus during full compression.
Secondary efficacy outcomes include: (a) death from any cause
within 90 days after enrollment, (b) non-fatal (recurrent) symptomatic
VTE within 90 days after enrollment, (c) readmission for ECOPD
within 90 days after enrollment, and (d) length of hospital stay.
The principal safety outcome is major bleeding within 90 days
after enrollment, defined according to the guidelines of the Interna-
tional Society of Thrombosis and Hemostasis,19 as acute clinically
overt bleeding associated with one or more among the following: a
decrease in hemoglobin of 2 g/dL or more, a transfusion of two or
more units of packed red blood cells, bleeding that occurs in at least
one of the following critical sites (intracranial, intraspinal, intraocular,
pericardial, intraarticular, intramuscular with compartment syndrome
or retroperitoneal), bleeding that is fatal (defined as a bleeding event
that the central independent committee adjudicate as the primary
cause of death or contributing directly to death) and bleeding that
necessitates surgical intervention. A bleeding event is classified as a
clinically relevant non-major bleeding event if it is overt (ie, is symp-
tomatic or visualized by examination) not meeting the criteria for
major bleeding, requires medical attention or is associated with dis-
comfort for the subject such as pain, or impairment of activities of
daily life.
A central independent adjudication committee whose members
are unaware of management allocation adjudicates all suspected study
outcomes during the study period.
2.5 | Surveillance and follow-up
The study requires the following scheduled visits: enrollment, 1 week,
1 month, and 3 months after randomization. Additional visits are per-
formed if new symptoms and/or signs of VTE or major bleeding occur
during the study period or anytime it is deemed necessary by the
investigator. Clinical examination, laboratory and diagnostic imaging
are performed if the patient develops symptoms or signs suggestive
of (recurrent) VTE.
FIGURE 1 Study flowchart
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2.6 | Sample size of the study
Previous studies have shown short-term rates of death, thromboem-
bolic events, or readmission of approximately 40% at day 90 among
patients who required hospital admission because of ECOPD.20 An
estimated 355 participants will be needed in each trial group to detect
a clinically important 10% absolute reduction in the primary outcome
(ie, from 40% to 30%) with 80% power at 5% significance level. The
10% reduction was based on consultation with primary and secondary
care colleagues (general practitioners and pulmonologists) who con-
sidered a 10% reduction to be small but clinically important. Since an
interim analysis showed that 3% of patients were lost to follow-up,
the Steering Committee anticipated a 5% loss to follow-up. This
inflated each study group to 373 patients, giving 746 patients in total.
2.7 | Statistical analysis
All analyses will be performed on the intention-to-treat population,
defined as all patients randomized, regardless of the management
actually received. A per-protocol analysis, excluding protocol viola-
tions, will be performed as a sensitivity analysis. The distribution of
continuous variables will be assessed by the Kolmogorov-Smirnov
test. Categorical variables are expressed as frequencies or percent-
ages and compared by χ2 statistics or Fisher's exact test. Continuous
variables will be summarized as the means ± SD or median and com-
pared using Student's t test (for normal data) and Mann-Whitney
U test (for non-normally distributed variables). Survival curves with
time-to-event data will be generated by the Kaplan-Meier method
and compared using the log-rank test. Comparisons between the two
groups will be performed using the Cox proportional hazard model. A
P-value <0.05 will be considered statistically significant. All analyses
will be performed with the use of the statistical programme
SPSS V.24.0.
Subgroup analyses will include: age (<75 vs ≥75 years), sex
(female vs male), COPD severity (FEV1 > 80%, 50% < FEV1 < 80%,
30% < FEV1 < 50%, and FEV1 < 30%), hospital volume (<300 beds
vs ≥300 beds), and season of the year (autumn, winter, spring, and
summer).
Two sensitivity analyses are planned for the primary outcome.
The first is an analysis of primary-outcome events after excluding
those patients in the intervention group with a diagnosis of isolated
sub-segmental PE. The second is an analysis of outcomes after exclud-
ing patients with a history of cancer.
2.8 | Study organization
The SLICE is an independent, investigator-initiated trial with an aca-
demic sponsor (Respiratory Department, Ramon y Cajal Hospital). The
Steering Committee (listed in the Appendix) assesses the progress,
provide scientific input, and address policy issues and operational
aspects of the protocol and recommendations of the Data and Safety
Monitoring Board (DSMB). At the end of the trial, the Steering Com-
mittee will meet in a closed session to discuss the trial results. Data
are collected, maintained and will be analyzed by S&H Medical in
Spain under the supervision of the Steering Committee members.
2.9 | Study Committees
The structure of the SLICE study includes a Steering Committee, a
central independent adjudication committee, and a DSMB.
The Steering Committee members have the final responsibility for
the conduction of the study as well as the verification and analyses of
all the study data. All the members of the Steering Committee have
access to the study data, vouch for their accuracy, and completeness;
they will contribute to the interpretation of the results, approve the
final version of the manuscript verifying the fidelity of the article to
the study protocol, and make the decision to submit the manuscript
for publication.
2.10 | Adjudication committee
A central independent adjudication committee, whose members are
unaware of management allocation, adjudicates all suspected outcome
events (see Outcomes).
2.11 | Data and safety monitoring board
An independent DSMB periodically reviews the study outcomes with
all information available concerning management allocation. The
DSMB is composed of three expert clinicians with experience in the
conduction and monitoring of clinical trials.
2.12 | Ethics and dissemination
The study is performed in accordance with the provisions of the Dec-
laration of Helsinki and local regulations. Protocol and amendments
have to be approved by the Institutional Review Board or Ethic Com-
mittee at each study center. The protocol and informed consent have
been approved by the Institutional Review Board of Ramon y Cajal
Hospital, and accepted by each participating center. Written informed
consent for participation in the trial is obtained from all enrolled
patients. Dissemination of the results will include conference presen-
tations and publications in peer-reviewed journals.
3 | RESULTS
Enrollment started in September 2014 and is expected to proceed
until 2020. Median age of the first 443 enrolled patients was 71 years
(interquartile range, 64-78), and 26% of patients were female.
4 | DISCUSSION
COPD patients may suffer from exacerbations, defined by an acute
worsening of respiratory symptoms beyond normal day-to-day varia-
tions and leading to a change in medication.8 Exacerbations are fre-
quent (about one in four patients experience at least 2 exacerbations
per year21), and are major determinants of health status in COPD.
COPD exacerbations requiring hospital admission are independent
predictors of mortality in COPD22 and also drive disease progression,
with approximately 25% of the lung function decline attributed to
exacerbations.23
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The SLICE trial is currently enrolling patients to assess the effi-
cacy and safety of an active strategy for the diagnosis and treatment
of PE in patients with ECOPD. The trial has the potential to improve
the management of exacerbations in patients with COPD. It is antici-
pated that the findings of this study will enhance our understanding
of the exacerbations of COPD. This rigorously designed trial will
address the role of PE in the decompensation of patients with COPD,
potentially leading to better care.
Previous studies and meta-analyses have assessed the prevalence
of PE in ECOPD.9–14 However, it is not known if all these PEs are clin-
ically important. The broad use of CTPA for the diagnosis of PE has
had minimal impact on the overall mortality related to PE, suggesting
that some extra cases of PE may not have been clinically relevant.24
To the best of our knowledge, this is the first randomized controlled
trial that will determine the value of detecting PEs in patients with
ECOPD.25
Our trial has some limitations. This is an open-label trial, and
ascertainment bias is inherent to the trial design. To mitigate potential
bias, all events are adjudicated by a committee whose members are
unaware of the intervention assignments. The decision to use a com-
posite outcome that includes readmissions for ECOPD might prove
challenging for the interpretation of results. There are some reasons
for including readmission as an outcome in the study protocol. First,
exacerbations of COPD are associated with accelerated loss of lung
function and death.26 Second, management of these outcomes may
reduce the risk of reaching other endpoints (mainly death). Finally,
some of readmissions for ECOPD might be caused by thromboem-
bolic events. Thus, the Steering Committee felt justified in using a
composite outcome that includes (recurrent) VTE and readmission for
ECOPD. In addition, the components of the composite variable will be
also analyzed separately.
In conclusion, the SLICE trial will provide high-quality evidence
regarding the risks as well as the benefits of using CTPA in the evalua-
tion of ECOPD.
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